Other
Immunosuppression
1
Pipeline Programs↗
7
Active Trials↗
6
Companies Involved↗
Immunosuppression is an early-stage landscape with 1 program across 6 companies. The most active players are Eli Lilly, Sumitomo Pharma Switzerland GmbH, Chong Kun Dang Pharmaceutical.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
46
clinical trials
Completed26 · 57%
Unknown status7 · 15%
Recruiting6 · 13%
Terminated5 · 11%
Withdrawn1 · 2%
Not yet recruiting1 · 2%
Clinical Trials
Trial Activity
46 trials
Combined Immunosuppression for Pediatric Crohn's Disease
Recruiting·—·Phase 4·NCT05043870·128 enrolled
Oral Microbial and Immunological Characterization of Patients With Immune Dysfunction
Recruiting·National Institute of Dental and Craniofacial Research (NIDCR)·N/A·NCT01568697·700 enrolled
Once-a-day Immunosuppression(CISECON_a_day)
Completed·—·Phase 4·NCT01964014·160 enrolled
COVID Protection After Transplant-Immunosuppression Reduction
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05077254·48 enrolled
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
Completed·—·Phase 2·NCT01012492·11 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)